Rivaroxaban for heparin-induced thrombocytopenia: adding to the evidence.
Department of Haematology, Singapore General Hospital, Singapore, Singapore.
Shin Yeu
SY
Ong
Department of Haematology, Singapore General Hospital, Singapore, Singapore.
Yun Ann
YA
Chin
Department of Haematology, Singapore General Hospital, Singapore, Singapore.
Hein
H
Than
Department of Haematology, Singapore General Hospital, Singapore, Singapore.
Chuen Wen
CW
Tan
Department of Laboratory Medicine, National University Hospital, Singapore, Singapore.
Eng Soo
ES
Yap
Department of Haematology, Singapore General Hospital, Singapore, Singapore.
Wan Hui
WH
Wong
Department of Haematology, Singapore General Hospital, Singapore, Singapore. ng.heng.joo@singhealth.com.sg.
Heng Joo
HJ
Ng
D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use*; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000069552:Rivaroxaban / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D006493:Heparin; D000069552:Rivaroxaban